學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
23andMe: Which Business Model(s)?
內容大綱
In June 2021, 23andMe completed their IPO with the VG Acquisition Corp, a special-purpose acquisition company. Due to the COVID-19 pandemic, there was more interest in genomics, as its value at scale had been demonstrated through many of the public health vaccine sequencing initiatives. Given these favorable market conditions and access to capital, was this the right time for 23andMe to shift their business model away from a consumer genetic testing company to a personalized health care company that collects genetic data to develop drugs and provide care? Did the company have the resources in place to achieve this vision? Could they do it alone or did they need to deepen their relationships with pharmaceutical companies, some of whom they were already in partnership with? In the age of growing consumer data privacy concerns, should Anne Wojcicki, 23andMe's chief executive officer and co-founder be wary of this approach of collecting genetic data?